Eradication	O
of	O
Central	O
Nervous	O
System	O
Leukemia	O
of	O
T	O
-	O
Cell	O
Origin	O
with	O
a	O
Brain	O
-	O
Permeable	O
LSD1	O
Inhibitor	O
.	O


PURPOSE	O
:	O
Lysine	O
-	O
specific	O
demethylase	O
1	O
(	O
LSD1	O
)	O
regulates	O
several	O
biological	O
processes	O
via	O
the	O
bifunctional	O
modulation	O
of	O
enhancer	O
functions	O
.	O


Recently	O
,	O
we	O
reported	O
that	O
LSD1	O
overexpression	O
is	O
a	O
founder	O
abnormality	O
of	O
T	O
-	O
cell	O
leukemogenesis	O
and	O
is	O
maintained	O
in	O
fully	O
transformed	O
T	O
-	O
cell	O
acute	O
lymphoblastic	O
leukemia	O
(	O
T	O
-	O
ALL	O
)	O
cells	O
.	O


On	O
the	O
basis	O
of	O
this	O
finding	O
,	O
we	O
attempted	O
to	O
develop	O
novel	O
LSD1	O
inhibitors	O
effective	O
for	O
T	O
-	O
ALL	O
with	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
involvement	O
.	O


EXPERIMENTAL	O
DESIGN	O
:	O
We	O
chemically	O
modified	O
the	O
prototype	O
LSD	O
inhibitor	O
tranylcypromine	O
(	O
TCP	O
)	O
and	O
screened	O
for	O
cytotoxicity	O
against	O
TCP	O
-	O
resistant	O
T	O
-	O
ALL	O
cell	O
lines	O
.	O


In	O
vivo	O
efficacy	O
of	O
novel	O
LSD1	O
inhibitors	O
was	O
examined	O
in	O
immunodeficient	O
mice	S-SPECIES
transplanted	O
with	O
luciferase	O
-	O
expressing	O
T	O
-	O
ALL	O
cell	O
lines	O
,	O
which	O
faithfully	O
reproduce	O
human	S-SPECIES
T	O
-	O
ALL	O
with	O
CNS	O
involvement	O
.	O


RESULTS	O
:	O
We	O
found	O
robust	O
cytotoxicity	O
against	O
T	O
-	O
ALL	O
cells	O
,	O
but	O
not	O
normal	O
bone	O
marrow	O
progenitors	O
,	O
for	O
two	O
N	O
-	O
alkylated	O
TCP	O
derivatives	O
,	O
S2116	O
and	O
S2157	O
.	O


The	O
two	O
compounds	O
induced	O
apoptosis	O
in	O
TCP	O
-	O
resistant	O
T	O
-	O
ALL	O
cells	O
in	O
vitro	O
and	O
in	O
vivo	O
by	O
repressing	O
transcription	O
of	O
the	O
NOTCH3	O
and	O
TAL1	O
genes	O
through	O
increased	O
H3K9	O
methylation	O
and	O
reciprocal	O
H3K27	O
deacetylation	O
at	O
superenhancer	O
regions	O
.	O


Both	O
S2116	O
and	O
S2157	O
significantly	O
retarded	O
the	O
growth	O
of	O
T	O
-	O
ALL	O
cells	O
in	O
xenotransplanted	O
mice	S-SPECIES
and	O
prolonged	O
the	O
survival	O
of	O
recipients	O
as	O
monotherapy	O
and	O
in	O
combination	O
with	O
dexamethasone	O
.	O


Notably	O
,	O
S2157	O
could	O
almost	O
completely	O
eradicate	O
CNS	O
leukemia	O
because	O
of	O
its	O
ability	O
to	O
efficiently	O
pass	O
through	O
the	O
blood	O
-	O
brain	O
barrier	O
.	O


CONCLUSIONS	O
:	O
These	O
findings	O
provide	O
a	O
molecular	O
basis	O
and	O
rationale	O
for	O
the	O
inclusion	O
of	O
a	O
brain	O
-	O
permeable	O
LSD1	O
inhibitor	O
,	O
S2157	O
,	O
in	O
treatment	O
strategies	O
for	O
T	O
-	O
ALL	O
with	O
CNS	O
involvement	O
.	O
